Exon scanning by reverse transcriptaseepolymerase chain reaction for detection of known and novel EML4-ALK fusion variants in nonesmall cell lung cancer

Cancer Genetics

Volumn 204, Issue 1, 2011, Pages 45-52

  Sanders, Heather R ^a   Li, Hai Rong ^a   Bruey, Jean Marie ^a,b   Scheerle, Jay A ^a   Meloni Ehrig, Aurelia M ^a   Kelly, JoAnn C ^a   Novick, Constance ^a   Albitar, Maher ^a,c  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b Biotheranostics   (United States)

^c Health Discovery Corporation   (United States)

Author keywords

EML4 ALK, Anaplastic lymphoma kinase, NSCLC, Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; HYBRID PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; DEOXYRIBONUCLEASE; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PRIMER DNA;

ACCURACY; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CONTROLLED STUDY; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 GENE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LUNG NON SMALL CELL CANCER; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; AMINO ACID SEQUENCE; CHEMISTRY; DNA SEQUENCE; GENETICS; LUNG TUMOR; METABOLISM; METHODOLOGY; MOLECULAR GENETICS;

ECHINODERMATA;

AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYRIBONUCLEASES; DNA PRIMERS; DNA, COMPLEMENTARY; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 79955656623     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.024     Document Type: Article

References (11)

1. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17.
2. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of nonesmall cell lung cancer. J Thorac Oncol 2009;4: 1450-1454.
3. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor. PF-02341066. J Clin Oncol 2009;27 (15s May 20 Suppl):3509 [Abstract].
4. Horn L, Pao W. EML4eALK: honing in on a new target in nonesmall cell lung cancer. J Clin Oncol 2009;27:4232-4235.
5. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4eALK fusion gene. Ann Surg Oncol 2010;17:889-897.
6. Wong DW, Leung EL, So KK, et al., University of Hong Kong Lung Cancer Study Group. The EML4eALK fusion gene is involved in various histologic types of lung cancers fromnonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115:1723-1733.
7. Takeuchi K, Choi YL, Togashi Y, et al. KIF5BeALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
8. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4eALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
9. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcriptionePCR screening for EML4eALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
10. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4eALK transforming gene in nonesmall cell lung cancer. Cancer Res 2008;68:4971-4976.
11. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4eALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.